VANGUARD Consortium Meeting 2024 in Turin
Last week, the VANGUARD face-to-face meeting took place in Turin, Italy, at the Molecular Biotechnology Center. The event was kindly hosted by Prof. Follenzi from the University of Eastern Piedmont
THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.
Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
9 partners from 5 countries
€ 6.8 million
01.01.2020 – 31.12.2024
Last week, the VANGUARD face-to-face meeting took place in Turin, Italy, at the Molecular Biotechnology Center. The event was kindly hosted by Prof. Follenzi from the University of Eastern Piedmont
We are excited to announce the launch of a new Patient Area on the VANGUARD website. While we have previously addressed common patient inquiries through an official letter available on
The latest research from the VANGUARD project has been featured on the EU research platform together with another EU-funded HemAcure project, highlighting their significant impact on medical science. The HemAcure
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874700